Angela DeMichele

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

Medicine, Oncology, Pharmacology +17

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

Rita Nanda, Minetta C. Liu, Christina Yau et al. · JAMA Oncology · 2020 · 706 citations · Full text

Medicine, Oncology, Pharmacology +16

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele et al. · New England Journal of Medicine · 2016 · 555 citations · Full text

Medicine, Oncology, Pharmacology +13